Nonselective beta-adrenoblocker carvedilol with vasodilating properties in the therapy of cardiovascular diseases


Cite item

Full Text

Abstract

Beta-blockers (BAB) widely used in clinical practice. Large clinical studies have shown that BAB can improve the prognosis in patients with cardiovascular diseases. However, recent years have increasingly raised the issue that BAB reduce the stroke risk in patients with arterial hypertension (AH) less effectively compared with other antihypertensive drugs, and are metabolically unsafe drugs. Carvedilol - nonselective beta1- and beta2- adrenoreceptors blocker with antioxidant action and vasodilating properties due to the additional blockade of alfa1-adrenergic receptors, has proven clinical efficacy in patients with hypertension, ischemic heart disease, congestive heart failure. In addition, large clinical studies of carvedilol safety demonstrated its application is not accompanied by disturbances in lipid and carbohydrate metabolism that creates additional benefits for the use of this drug in clinical practice.

References

  1. Мельник М.В., Шилов А.М. Карведилол в лечении сердечно-сосудистых заболеваний // РМЖ. 2007. № 15(9). С. 736-742.
  2. Воронков Л.Г. Карведилол - уникальная молекула с уникальными клиническими возможностями // Здоровье Украины. 2004 № 3 (91).
  3. Yue TL, Mc Kenna PJ, Lysko PG. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper Atherosclerosis 1992;97:209-16.
  4. Feuerstein GS, Ruffolo RR. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996;17(Suppl. B):24-29.
  5. Lindholm LH, Carlsberg B, Samuelsson A meta-analysis. Lancet 2005;366:1545-53.
  6. Gress TW, Nieto J, Shahar Y, et al. N Eng J Med 2000;342:905-12.
  7. Lindholm LH, et al. LIFE study. Lancet 2002;359:1004-10.
  8. Dahlof B, et al. ASCOT Investigators. Lancet 2005;366:895-90.
  9. Jacob S, et al. Am О Hypertens 1998;11:1258-65.
  10. Bakris GL, Fonseca V, Katholi RE, at al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension. A Randomized Controlled Trial JAMA 2004;292(18).
  11. Мычка В.Б., Чазова И.Е. Применение карведилола у больных с метаболическим синдромом // Системные гипертензии. 2005. № 7(2).
  12. Panagiotis C Stafylas and Pantelis A Sarafidis Carvedilol in hypertension treatment Vasc Health Risk Manag 2008;4(1):23-30.
  13. Weber MA, Bakris GL, Tarka EA, et al. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich) 2006;8:840-49.
  14. Devereaux PJ, Scott Beattie W, Choi PTL, et al. How strong is the evidence for the use of perioperative b-blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 2005;331:313-21.
  15. Feuerstein R, Yue TL. A potent antioxidant, SB209995, inhibits oxy gen-radical-mediated lipid peroxidation and cytotoxicity. Pharmacology 1994;48:385-91.
  16. Hauf-Zachariou U, Blackwood RA, Gunawardena KA, et al. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur J Clin Pharmacol 1997;52:95-100.
  17. Van der Does R, Hauf-Zachariou U, Pfarr E, et al. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pec toris. Am J Cardiol 1999;83:643-49.
  18. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial Lancet 2001;357:1385-90.
  19. Poole-Wilson PA, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomized controlled trial. Lancet 2003;362(9377):7-13.
  20. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349.
  21. Randomized, pacebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997;349:375-80.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies